Researchers Created First ARMS2 Mouse Model for AMD
A new transgenic mouse model replicates age-related macular degeneration phenotypes, enabling potential new drug trials.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you believe animal research is essential for developing new medical treatments?
Researchers have used CRISPR-Cas9 to develop the first mouse model containing the human ARMS2 A69S variant, the primary genetic risk factor for age-related macular degeneration (AMD). This research-stage model allows scientists to study mechanisms of retinal degradation that were previously impossible to replicate in rodents.
Why it matters
Because rodents naturally lack the ARMS2 gene, previous attempts to study this high-risk variant were limited in scope. This new model provides a necessary platform to investigate molecular drivers of retinal health and screen for therapeutic interventions for AMD.
The study utilized CRISPR-Cas9 to insert the human ARMS2 gene onto mouse Chromosome 7, placing the sequence 3.5 kb upstream of Htra1. By 12 months, these mice exhibit outer nuclear layer thinning and reduced scotopic ERG amplitudes compared to wild-type controls.
The players
CRISPR-Cas9
A gene-editing tool derived from bacterial immune systems that allows for precise, site-specific modifications to DNA sequences.
The details
The model was generated by integrating the human ARMS2 gene, which is absent in native rodent genomes, into the mouse Chromosome 7 locus while maintaining its native promoter orientation. Expression was localized to retinal horizontal cells and the retinal pigment epithelium (RPE) — the pigmented cell layer that nourishes retinal visual cells. The resulting retinal degradation is linked to decreased mitochondrial respiration and a reduction in mitochondrial DNA copy number, providing a measurable metabolic marker for disease progression.
Timeline
Postnatal day 14: Transcriptomic profiling was conducted on the retina and RPE.
12 months: Mice develop AMD-relevant retinal phenotypes.
The Tech Race
The Chromosome 10q26 region remains the highest-known genetic risk factor for AMD, yet research has long been stalled by the absence of the ARMS2 gene in rodent models. This development marks a major departure from past work, enabling researchers to move beyond correlative genetic data toward functional, in-vivo experimentation.
This research-stage model is currently limited to laboratory use and does not offer direct clinical benefits for patients today. It serves as a necessary prerequisite for future drug discovery efforts, potentially informing how pharmaceutical companies design and screen new candidates for AMD treatment.
The takeaway
This model provides the first platform to study human-specific ARMS2 risk variants in a living system. Researchers should track upcoming drug screening studies that utilize this model to see if it successfully leads to candidate therapeutics targeting mitochondrial dysfunction in the retina.
Further reading
Learn more about the latest developments in Biotech.
More information
Access the complete biorxiv research study publication for full methodology.
Source note: This article includes information reported by Biorxiv.
Live Poll
Do you believe animal research is essential for developing new medical treatments?
